Aptose Biosciences Faces Delisting Concerns
Ticker: APTOF · Form: 8-K · Filed: Mar 1, 2024 · CIK: 882361
Sentiment: bearish
Topics: delisting, compliance, listing-rule
TL;DR
Aptose might get kicked off Nasdaq - big trouble.
AI Summary
Aptose Biosciences Inc. filed an 8-K on March 1, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The filing indicates potential issues with meeting Nasdaq's continued listing requirements, though specific details regarding the rule or standard were not immediately clear from the provided text. The company's fiscal year ends on December 31st.
Why It Matters
This filing signals potential financial distress or non-compliance with exchange rules, which could lead to the company's stock being delisted, impacting investor confidence and liquidity.
Risk Assessment
Risk Level: high — A notice of delisting directly threatens the company's ability to trade on a major exchange, posing a significant risk to its operations and stock value.
Key Players & Entities
- Aptose Biosciences Inc. (company) — Registrant
- Nasdaq (company) — Stock Exchange
- Lorus Therapeutics Inc. (company) — Former Company Name
- Imutec Pharma Inc (company) — Former Company Name
FAQ
What specific listing rule or standard has Aptose Biosciences Inc. failed to meet?
The provided text indicates a 'Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard' but does not specify which particular rule or standard has been violated.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is February 29, 2024.
What is the primary business classification for Aptose Biosciences Inc. according to the SIC code?
The Standard Industrial Classification (SIC) code is 2836, which corresponds to 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)'.
When did Aptose Biosciences Inc. change its name from Lorus Therapeutics Inc.?
The company changed its name from Lorus Therapeutics Inc. on September 5, 2014.
What is the filing date of this 8-K report?
This 8-K report was filed on March 1, 2024.
Filing Stats: 683 words · 3 min read · ~2 pages · Grade level 12.1 · Accepted 2024-03-01 17:00:16
Filing Documents
- f8k_030124.htm (8-K) — 23KB
- 0001171843-24-001127.txt ( ) — 193KB
- apto-20240229.xsd (EX-101.SCH) — 3KB
- apto-20240229_lab.xml (EX-101.LAB) — 33KB
- apto-20240229_pre.xml (EX-101.PRE) — 22KB
- f8k_030124_htm.xml (XML) — 4KB
01
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On February 29, 2024, Aptose Biosciences Inc. (the "Company") received a deficiency letter (the "Deficiency Letter") from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that the Company's recent issuance of securities to Hanmi Pharmaceutical Co., Ltd. (the "Hanmi Transaction") violated 5635(d) because the Company did not obtain shareholder approval prior to such issuance. Nasdaq stated that completion of the Hanmi Transaction involved the issuance of greater than 20% of the issued and outstanding common shares of the Company at a discount to the Nasdaq official closing price on January 25, 2024, the date of the subscription agreement between the Company and Hanmi. The Deficiency Letter has no immediate effect on the listing of the Company's common shares, and its common shares will continue to trade on The Nasdaq Capital Market under the symbol "APTO" at this time. The Company's common shares continue to trade on the Toronto Stock Exchange ("TSX") under the symbol "APS". The Company's listing on the TSX is independent and will not be affected by the Nasdaq listing status. In accordance with the Nasdaq Listing Rules, the Company has been given forty five (45) calendar days, or until April 14, 2024, to submit a plan to regain compliance. If Nasdaq accepts the Company's plan, Nasdaq can grant an extension of up to 180 calendar days from the date of the Deficiency Letter to evidence compliance. Although the Company believes that the Hanmi Transaction was completed in accordance with the Nasdaq Listing Rules, the Company respects Nasdaq's query and intends to work with Nasdaq to resolve Nasdaq's concerns and will consider available options to regain compliance. However, there can be no assurance that the Company will be able to regain compliance with the applicable Nasdaq Listing Rules.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits Exhibit No. Description of Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 1, 2024 APTOSE BIOSCIENCES INC. By: /s/ Fletcher Payne Name: Fletcher Payne Title: Senior Vice President and Chief Financial Officer